StockData
Lucid Diagnostics Inc. logo

Lucid Diagnostics Inc. (LUCD) stock

LUCDNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 7/3038% above fair value
$0.39−0.02 (-5.25%)

Close on Nov 19, 2026Market cap $78.51MP/E –Yield –

Lucid Diagnostics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Lucid Diagnostics's free cash flow for the twelve months ending Mar 31, 2023 was -$34.10M. For fiscal 2025 it was -$46.68M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$46.68M–
FY2024Dec 31, 2024-$44.44M–
FY2022Dec 31, 2022-$32.89M–
FY2021Dec 31, 2021-$18.53M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$11.32M–
Q1 FY2026Mar 31, 2026-$12.32M–
Q2 FY2025Jun 30, 2025-$10.57M–
Q1 FY2025Mar 31, 2025-$12.56M–
Q1 FY2023Mar 31, 2023-$7.14M–
Q4 FY2022Dec 31, 2022-$4.26M–
Q3 FY2022Sep 30, 2022-$7.35M–
Q2 FY2022Jun 30, 2022-$15.36M–
Q1 FY2022Mar 31, 2022-$5.92M–
Q4 FY2021Dec 31, 2021-$10.70M–
Q3 FY2021Sep 30, 2021-$2.21M–
Q2 FY2021Jun 30, 2021-$2.30M–
Q1 FY2021Mar 31, 2021-$3.32M–

More Lucid Diagnostics figures

See a number that looks wrong?